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Influence of diet on the gut microbiome 
and implications for human health
Rasnik K. Singh1, Hsin‑Wen Chang2, Di Yan2, Kristina M. Lee2, Derya Ucmak2, Kirsten Wong2, Michael Abrouk3, 
Benjamin Farahnik4, Mio Nakamura2, Tian Hao Zhu5, Tina Bhutani2 and Wilson Liao2* 
Abstract 
Recent studies have suggested that the intestinal microbiome plays an important role in modulating risk of several 
chronic diseases, including inflammatory bowel disease, obesity, type 2 diabetes, cardiovascular disease, and cancer. 
At the same time, it is now understood that diet plays a significant role in shaping the microbiome, with experiments 
showing that dietary alterations can induce large, temporary microbial shifts within 24 h. Given this association, 
there may be significant therapeutic utility in altering microbial composition through diet. This review systematically 
evaluates current data regarding the effects of several common dietary components on intestinal microbiota. We 
show that consumption of particular types of food produces predictable shifts in existing host bacterial genera. Fur‑
thermore, the identity of these bacteria affects host immune and metabolic parameters, with broad implications for 
human health. Familiarity with these associations will be of tremendous use to the practitioner as well as the patient.
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Background
The gut microbiome
The human gut microbiome encompasses  1014 resident 
microorganisms, including bacteria, viruses, fungi, and 
protozoa, that are commensal with the human intestinal 
tract [1]. Among these, bacteria represent the most well 
studied group and will be the main focus of this review. 
Overall the predominant bacterial groups in the micro-
biome are gram positive Firmicutes and gram negative 
Bacteroidetes [2, 3]. Recently, it has been shown that 
microbiota can effectively be subdivided into different 
enterotypes, each enriched by particular bacterial genera, 
but that all seem to share high functional uniformity [4]. 
This uniformity exists regardless of several host proper-
ties, such as age, sex, body mass index, and nationality 
[5].
The majority of microorganisms reside within the 
more distal parts of the digestive tract, where their bio-
mass surpasses  1011 cells per gram content [6]. Microbes 
in the distal gut contribute to host health through bio-
synthesis of vitamins and essential amino acids, as well 
as generation of important metabolic byproducts from 
dietary components left undigested by the small intes-
tine [7]. Short chain fatty acid (SCFA) byproducts such 
as butyrate, propionate, and acetate act as a major energy 
source for intestinal epithelial cells and may therefore 
strengthen the mucosal barrier [8]. Additionally, studies 
conducted using germ-free mice suggest that the micro-
biota directly promote local intestinal immunity through 
their effects on toll-like receptor (TLR) expression [9], 
antigen presenting cells, differentiated T cells, and lym-
phoid follicles [10, 11], as well as by affecting systemic 
immunity through increased splenic  CD4+ T cells and 
systemic antibody expression [12].
These recorded benefits and more have led to growing 
interest in the ability to modify the gut microbiota. An 
acute change in diet—for instance to one that is strictly 
animal-based or plant-based—alters microbial com-
position within just 24  h of initiation, with reversion to 
baseline within 48  h of diet discontinuation [13]. Fur-
thermore, the gut microbiome of animals fed a high-fat 
or high-sugar diet is more prone to circadian rhythm 
disruption [14]. Studies also suggest that overwhelming 
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systemic stress and inflammation—such as that induced 
via severe burn injury—can also produce characteristic 
acute changes in the gut microbiota within just one day 
of the sustained insult [15].
The microbiome in disease
Studies examining the composition and role of the 
intestinal microbiome in different disease states have 
uncovered associations with inflammatory bowel dis-
eases (IBD), inflammatory skin diseases such as psoria-
sis and atopic dermatitis, autoimmune arthritis, type 2 
diabetes, obesity, and atherosclerosis. For instance, IBD 
patients tend to have less bacterial diversity as well as 
lower numbers of Bacteroides and Firmicutes—which 
together may contribute to reduced concentrations of 
microbial-derived butyrate. Butyrate and other SCFAs 
are thought to have a direct anti-inflammatory effect in 
the gut [16]. Furthermore, different indices of Crohn’s 
disease activity have each been characterized by specific 
gut mucosa-attached bacteria, that in turn are signifi-
cantly influenced by anti-TNF therapy [17]. The relative 
abundance of different bacteria may mediate intesti-
nal inflammation and Crohn’s disease activity through 
effects on local regulatory T cell populations [17, 18]. 
Furthermore, overrepresentation analysis has shown that 
enzymes enriched in IBD microbiomes are more fre-
quently involved in membrane transport, which could 
support a “leaky gut hypothesis” contributing to the 
disease state [19, 20]. Interestingly, autoimmune Th17 
differentiation from naïve T cells appears to be depend-
ent on the segmented filamentous bacteria. Studies have 
shown that Th17 cells are absent in the small-intestinal 
lamina propria of germ-free animals, which is the major 
site of their differentiation. Furthermore, introduction 
of segmented filamentous bacteria is sufficient to trig-
ger autoimmune arthritis in these animals through pro-
motion of Th17 cell development in the lamina propria 
and spleen [20, 21]. The gut microbiota of patients with 
type 2 diabetes has been functionally characterized with 
diabetes-associated markers, showing enriched mem-
brane transport of sugars and branched-chain amino 
acids, xenobiotic metabolism, and sulphate reduction 
along with decreased bacterial chemotaxis, butyrate syn-
thesis and metabolism of cofactors and vitamins [22]. 
Obesity has been characterized by an altered intestinal 
Bacteroides:Firmicutes ratio, with greater relative abun-
dance of Firmicutes. Furthermore, studies involving 
microbiota transplantation from obese to lean mice have 
shown that the obese phenotype is transmissible and may 
be promoted by microbiota that have increased capacity 
to harvest energy from the host diet [23]. Risk of athero-
sclerosis has similarly been linked to the gut microbiota, 
in particular due to enhanced metabolism of choline 
and phosphatidylcholine that produces the proathero-
genic compound, trimethylamine-N-oxide (TMAO) [24]. 
A recent study also demonstrated that gut bacteria can 
produce significant amounts of amyloid and lipopolysac-
charides, which are key players in the pathogenesis of 
Alzheimer’s disease [25]. These observations illustrate the 
important role of microorganisms in human health and 
suggest that manipulating them may influence disease 
activity. While the microbiome of a healthy individual is 
relatively stable, gut microbial dynamics can certainly be 
influenced by host lifestyle and dietary choices [26].
In this review, we comprehensively explore the ability 
of the host diet to modulate gut bacteria, with the hope 
that this knowledge will guide our understanding of how 
dietary choices impact human health through alteration 
of the gastrointestinal ecosystem (Fig. 1, Table 1).
Methods
We performed a systematic literature review in Septem-
ber 2015 by searching the electronic MEDLINE database 
via PubMed. Search terms included combinations of the 
terms “microbiota”, “intestinal mucosa/microbiology”, 
“gastrointestinal tract/microbiology”, “gastrointestinal 
diseases/microbiology”, with “diet”, “food”, “polysaccha-
rides”, “carbohydrates”, “proteins”, “meat”, “fat”, “lactose”, 
“oligofructose”, “prebiotics”, “probiotics”, “polyphenols”, 
“starch”, “soy”, “sucrose”, “fructose”, “diet, vegetarian”, 
“diet, western”, “cereals”, “dietary fiber”, and “dietary sup-
plements”. Articles were reviewed independently by 
two investigators, R.K.S. and K.M.L, and this was adju-
dicated by W.L. We limited our search to articles avail-
able in English, human studies, and those published 
between 1970 and 2015. We excluded studies that did not 
explicitly address the effect of a dietary intervention on 
microbial composition. Manual searches through refer-
ence lists of the articles were also performed to identify 
additional studies. This resulted in a total of 188 arti-
cles being selected for inclusion in this review. Studies 
describing the relationship between specific dietary com-
ponents and intestinal microbiota composition ranged 
from subject number n = 3 to n = 344, with a majority 
of studies clustered around subject number n  =  20 to 
70. Study designs were primarily randomized controlled 
trials, cross-sectional studies, case–control studies, and 
in  vitro studies. In addition to human studies, several 
animal studies were also included to demonstrate dietary 
impact on the microbiome under controlled experimen-
tal conditions.
Diet and microbiota
Protein
The effects of dietary protein on the gut microbiota 
were first described in 1977. A culture-based study 
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demonstrated lower counts of Bifidobacterium adoles-
centis and increased counts of Bacteroides and Clostridia 
in subjects consuming a high beef diet when compared 
to subjects consuming a meatless diet [27]. With the 
advances of 16S rRNA sequencing, several studies have 
been able to comprehensively investigate the impact of 
dietary protein on gut microbial composition (studies 
listed in Table 2). Participants were given different forms 
of protein across these studies, such as heavy animal-
based protein from meats, eggs, and cheeses; whey pro-
tein; or purely vegetarian sources such as pea protein. 
A majority of the studies noted that protein consump-
tion positively correlates with overall microbial diversity 
[13, 28–30]. For example, consumption of whey and pea 
protein extract has been reported to increase gut-com-
mensal Bifidobacterium and Lactobacillus, while whey 
additionally decreases the pathogenic Bacteroides fra-
gilis and Clostridium perfringens [31–33]. Pea protein 
has also been observed to increase intestinal SCFA lev-
els, which are considered anti-inflammatory and impor-
tant for maintenance of the mucosal barrier [34]. On the 
contrary, counts of bile-tolerant anaerobes such as Bac-
teroides, Alistipes, and Bilophila were noted to increase 
with consumption of animal-based protein  (Fig.  2) [13, 
29, 30]. This observation can be further supported by an 
independent study in which the researchers compared 
the microbiota of Italian children with that of children 
in a rural African village. Italian children, who ate more 
animal protein, were enriched for Bacteroides and Alis-
tipes in their microbiota [35]. Notably, one study com-
paring calorically equivalent high animal protein with 
high-carbohydrate/fiber plant-based diets reported that 
subjects’ weights on the plant-based diet remained sta-
ble, but decreased significantly by day 3 of the animal 
protein-based diet (q < 0.05). Although high protein/low 
carbohydrate intake may promote greater relative weight 
loss, this dietary pattern may pose a detriment to health. 
One study found that subjects with a high protein/low 
carbohydrate diet have reduced Roseburia and Eubac-
terium rectale in their gut microbiota and a decreased 
proportion of butyrate in their feces [36]. In their study, 
De Filippo et  al. [35] similarly noted fewer fecal SCFAs 
in Italian subjects who consumed a protein-rich diet. As 
an interesting clinical correlate, several studies have dem-
onstrated that IBD patients possess lower fecal counts of 
Roseburia and other butyrate-producing bacteria than 
Fig. 1 Impact of diet on the gut microbiome and human health
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healthy subjects. Healthy subjects, on other other hand, 
have 10-fold more abundant E. rectale in their intestines 
[37–39]. These gut bacterial changes may be responsible 
for the finding in a large participant prospective study 
(n = 67,581) that high total protein intake, especially ani-
mal protein, is associated with a significantly increased 
risk of IBD [40]. Furthermore, several microbial genera 
promoted by intake of red meat have also been associ-
ated with increased levels of trimethylamine-N-oxide 
(TMAO), a proatherogenic compound that increases risk 
of cardiovascular disease [41].
Mouse studies have revealed that high protein intake 
increases insulin-like growth factor 1 (IGF-1) levels, 
which are in turn associated with an increased risk of 
cancer, diabetes, and overall mortality. In one study, 
plant-derived proteins are associated with lower mortal-
ity than animal-derived proteins [42]. Accordingly, long-
term practice of such dietary habits may increase risk of 
colonic disease and others. It is important to note that 
animal-based diets are often high in fat, in addition to 
protein. Dietary fat can also affect microbial composition; 
therefore, further studies will be required to investigate 
in what capacity each individual macromolecule impacts 
the bacterial communities and how they act in concert.
Fats
Consumption of high saturated and trans fat diets is 
thought to increase the risk of cardiovascular disease 
through upregulation of blood total- and LDL-choles-
terol [43, 44]. On the other hand health-promoting fats, 
Table 1 Overview of select gut bacterial genera and species commonly affected by diet
spp species, SCFA short chain fatty acid, LPS lipopolysaccharide, IBD inflammatory bowel disease, TH T helper, FG Fournier’s gangrene, HS hidradenitis suppurativa, UTI 
urinary tract infection(s), TLR toll-like receptor, MALT mucosa-associated lymphoid tissue
a A. putredinis does not produce pigment and is susceptible to bile
Bacteria Basic features Associated physiologic changes Associated disease states References
Bifidobacterium spp. Gram positive obligate anaerobe 
branched; nonmotile
SCFA production; improve gut 
mucosal barrier; lower intestinal 
LPS levels
Reduced abundance in obesity [166, 167]
Lactobacillus spp. Gram positive facultative anaerobe 
rod‑shaped
SCFA production; anti‑inflammatory 
and anti‑cancer activities
Attenuate IBD [168, 169]
Bacteroides spp. Gram negative obligate anaerobe 
rod‑shaped; variable motility
Activate CD4 + T cells Increased abundance in IBD [170–173]
Alistipes spp. Gram negative obligate anaerobe 
rod‑shaped; bile‑resistant and 
pigment‑producinga
Reported in tissue from acute appen‑
dicitis and perirectal and brain 
abscesses
[174]
Bilophila spp. Gram negative obligate anaerobe 
urease‑positive, bile resistant, 
catalase‑positive
Promote pro‑inflammatory  TH1 
immunity
B. wadsworthia observed in colitis, 
perforated and gangrenous 
appendicitis, liver and soft tissue 
abscesses, cholecystitis, FG, empy‑
ema, osteomyelitis, and HS
[175, 176]
Clostridium spp. Gram positive obligate anaerobe 
rod‑shaped; spore‑forming
Promote generation of  TH17 cells Several spp. are pathogenic causing 
tetanus, botulism, gas gangrene, or 
pseudomembranous colitis
[177, 178]
Roseburia spp. Gram variable obligate anaerobe 
curved rod‑shaped; motile
SCFA production Reduced abundance in IBD [179]
Eubacterium spp. Gram positive obligate anaerobe 
rod‑shaped
SCFA production; form beneficial 
phenolic acids
Reduced abundance in IBD [180, 181]
Enterococcus spp. Gram positive facultative anaerobe 
cocci
Several spp. are pathogenic causing 
UTI, endocarditis, or bacteremia
[182]
Faecalibacterium 
prausnitzii
Gram positive obligate anaerobe 
rod‑shaped; nonmotile
SCFA production; anti‑inflammatory 
effects
Reduced abundance in IBD and 
obesity
[183, 184]
Akkermansia mucin-
iphila
Gram negative obligate anaerobe 
oval‑shaped; nonmotile
Anti‑inflammatory effects Reduced abundance in IBD, obesity, 
and psoriatic arthritis
[53, 133, 185]
Escherichia coli Gram negative facultative anaer‑
obe rod‑shaped
TLR‑activation Increased abundance in IBD gastroen‑
teritis, UTI, and meningitis
[186–188]
Helicobacter pylori Gram negative microaerophilic 
helix‑shaped; motile
Gastritis; ulcers; MALT cancers [189, 190]
Streptococcus spp. Gram positive facultative anaerobe 
cocci
Some spp. are pathogenic caus‑
ing meningitis, pneumonia, and 
endocarditis
[191]
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such as mono and polyunsaturated fats, are crucial in 
alleviating risk of chronic disease. The typical Western 
diet is both high in saturated and trans fats while low in 
mono and polyunsaturated fats, therefore predisposing 
regular consumers to many health problems [45–47]. 
Several human studies have suggested that a high-fat diet 
increases total anaerobic microflora and counts of Bacte-
roides [26, 29, 48, 49] (studies listed in Table 3). To spe-
cifically investigate the effects of different kinds of dietary 
fat on human gut microbiota, Fava et  al. had subjects 
consume diets of varying fat content. The authors noted 
that consumption of a low fat diet led to increased fecal 
abundance of Bifidobacterium with concomitant reduc-
tions in fasting glucose and total cholesterol, compared 
to baseline. On the other hand, a high saturated fat diet 
increased the relative proportion of Faecalibacterium 
prausnitzii. Finally, subjects with high monounsatu-
rated fat intake did not experience shifts in the relative 
abundance of any bacterial genera, but did have over-
all reduced total bacterial load and plasma total- and 
LDL-cholesterol [49]. In line with these findings, con-
sumption of salmon–which is high in mono and polyun-
saturated fats—was not noted to alter fecal microbiota 
composition in 123 subjects either [50]. Studies in rats 
have shown that intake of a high-fat diet results in con-
siderably less Lactobacillus intestinalis and dispropor-
tionately more propionate and acetate producing species, 
including Clostridiales, Bacteroides, and Enterobacteri-
ales. Furthermore, the abundance of Lactobacillus intes-
tinalis is negatively correlated with rat fat mass and body 
weight [51]. Microbial changes have also been shown to 
control metabolic endotoxemia-induced inflammation in 
high-fat diet consuming mice [52]. Mouse studies have 
also compared the differential effects of various lipids 
on intestinal microflora. A comparison of lard-derived 
and fish oil-derived lipids revealed that Bacteroides and 
Bilophila were increased in lard-fed mice, while Actino-
bacteria (Bifidobacterium and Adlercreutzia), lactic acid 
bacteria (Lactobacillus and Streptococcus), and Verru-
comicrobia (Akkermansia muciniphila) were increased 
Fig. 2 Impact of dietary protein on intestinal microbiota and health outcomes. SCFA’s short chain fatty acids, TMAO trimethylamine N‑oxide, Tregs T 
regulatory cells, CVD cardiovascular disease; IBD inflammatory bowel disease
Table 2 Effects of protein on gut microbiota
Arrow thickness corresponds to relative number of studies supporting the relationship
Microbial 
diversity
Bifidobacteria Lactobacilli Bacteroides Alistipes Bilophila Clostridia Roseburia Eubacterium 
Rectale
References
Animal  
protein
↑ ↑↓ ↑↓ ↑ ↑ ↑ ↓ ↑↓ [13, 29–35, 
38–40]
Whey protein 
extract
↑ ↑ ↑ ↓ ↓ [32, 33]
Pea protein 
extract
↑ ↑ ↑ [31]
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in fish-oil-fed mice. Furthermore, lard-fed mice had 
increased systemic TLR activation, white adipose tissue 
inflammation, and impaired insulin sensitivity compared 
to mice consuming fish oil. The authors demonstrated 
that these findings are at least partly due to differences in 
gut microbiota between the two groups; transplantation 
of microbiota from one group to the other after antibiotic 
administration not only enriched the transplant recipi-
ent’s gut with dominant genera from the donor species, 
but also replicated the donor’s inflammatory and meta-
bolic phenotypes. These results indicate that gut micro-
biota may promote metabolic inflammation through TLR 
signaling upon challenge with a diet rich in saturated 
lipids (Fig. 3) [53].
Carbohydrates
Digestible carbohydrates (starch, sugars)
Carbohydrates are possibly the most well studied dietary 
component for their ability to modify the gut microbi-
ome (studies listed in Table  4). Carbohydrates exist in 
two varieties: digestible and non-digestible. Digestible 
carbohydrates are enzymatically degraded in the small 
intestine and include starches and sugars, such as glucose, 
fructose, sucrose, and lactose. Upon degradation, these 
compounds release glucose into the bloodstream and 
stimulate an insulin response [54]. Human subjects fed 
high levels of glucose, fructose, and sucrose in the form of 
date fruits [55] had increased relative abundance of Bifi-
dobacteria, with reduced Bacteroides [56]. In a separate 
study, the addition of lactose to the diet replicated these 
same bacterial shifts while also decreasing Clostridia spe-
cies. Notably, many Clostridium cluster XIVa species have 
been associated with irritable bowel syndrome [57, 58]. 
Lactose supplementation has additionally been observed 
to increase the fecal concentration of beneficial SCFAs 
[58]. These findings are quite unexpected given that lac-
tose is commonly thought of as a potential gastrointes-
tinal irritant (e.g. lactose intolerance). Further studies 
validating these observations can help clarify the effects of 
lactose.
The artificial sweeteners saccharin, sucralose, and 
aspartame represent another dietary controversy. 
Fig. 3 Impact of dietary fats on intestinal microbiota and host metabolism. TLR toll‑like receptor, WAT white adipose tissue, LDL low‑density lipopro‑
tein
Table 3 Effects of fats on gut microbiota
a Lactic acid bacteria include Lactobacillus and Streptococcus
Lactic acid 
 bacteriaa
Bifidobacteria Clostridiales Bacteroides Bilophila Faecalibacte‑
rium prausnitzii
Akkermansia 
muciniphila
References
High fat ↓ ↑ ↑ [30, 49, 51, 52]
Low fat ↑ [49]
High saturated fat ↑ ↑ ↑ [26, 49]
High unsaturated 
fat
↑ ↑ ↑ [45, 49, 50]
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Artificial sweeteners were originally marketed as a 
health-conscious, no-calorie food option that could 
be used to replace natural sugar. Recent evidence from 
Suez et al. suggests that consumption of all types of arti-
ficial sweeteners is actually more likely to induce glu-
cose intolerance than consumption of pure glucose and 
sucrose. Interestingly, artificial sweeteners are thought 
to mediate this effect through alteration of gut microbi-
ota. For instance, saccharin-fed mice were noted to have 
intestinal dysbiosis with increased relative abundance 
of Bacteroides and reduced Lactobacillus reuteri [59]. 
These microbial shifts directly oppose those induced by 
intake of natural sugars (glucose, fructose, and sucrose)-
as mentioned above. The evidence seems to suggest 
that, contrary to popular belief, artificial sweeteners 
may actually be unhealthier to consume than natural 
sugars.
Non‑digestible carbohydrates (fiber)
In contrast to digestible carbohydrates, non-digestible 
carbohydrates such as fiber and resistant starch are not 
enzymatically degraded in the small intestine. Rather, 
they travel to the large intestine where they undergo 
fermentation by resident microorganisms. Accordingly, 
dietary fiber is a good source of “microbiota accessi-
ble carbohydrates” (MACs), which can be utilized by 
microbes to provide the host with energy and a carbon 
source [25, 60, 61]. In the process, they are able to modify 
the intestinal environment. This property of fibers war-
rants their additional designation as prebiotics, which 
by definition are non-digestible dietary components that 
benefit host health via selective stimulation of the growth 
and/or activity of certain microorganisms [62]. Sources 
of prebiotics include soybeans, inulins, unrefined wheat 
and barley, raw oats, and non-digestible oligosaccharides 
such as fructans, polydextrose, fructooligosaccharides 
(FOS), galactooligosaccharides (GOS), xylooligosaccha-
rides (XOS), and arabinooligosaccharides (AOS) [63]. A 
diet that is low in these substances has been shown to 
reduce total bacterial abundance [64]. On the other hand, 
high intake of these carbohydrates in 49 obese subjects 
resulted in an increase in microbiota gene richness [30]. 
Regarding their effects on specific bacterial genera, many 
studies suggest that a diet rich in non-digestible carbo-
hydrates most consistently increases intestinal bifidobac-
teria and lactic acid bacteria (studies listed in Table  5). 
The numerous studies listed in Table  5 corresponding 
to each type of prebiotic listed above, corroborate these 
findings. For instance, non-digestible carbohydrate diets 
that are rich in whole grain and wheat bran are linked 
to an increase in gut Bifidobacteria and Lactobacilli 
[65, 66]. Other non-digestible carbohydrates, such as 
resistant starch and whole grain barley, appear to also 
increase abundance of Ruminococcus, E. rectale, and 
Roseburia [3, 67, 68]. Additionally, FOS-, polydextrose-, 
and AOS-based prebiotics have been observed to reduce 
Clostridium [69–72] and Enterococcus species [73–76]. A 
cross-sectional study of 344 patients with advanced colo-
rectal adenomas revealed that Roseburia and Eubacte-
rium were significantly less prevalent, while Enterococcus 
and Streptococcus were more prevalent in these subjects 
compared to healthy controls. Reduced dietary fiber hab-
its and consistently lower SCFA production were also 
observed in the adenoma group [77].
Table 4 Effects of natural and artificial sugar on gut microbiota
Bifidobacteria Bacteroides Clostridia Lactobacilli References
Glucose ↑ ↓ [55, 56]
Fructose ↑ ↓ [55, 56]
Sucrose ↑ ↓ [55, 56]
Lactose ↑ ↓ ↓ ↑ [58]
Artificial sweeteners ↓ ↑ ↓ ↓ [59]
Table 5 Effects of non-digestible carbohydrates on gut microbiota
Arrow thickness corresponds to relative number of studies supporting the relationship
Bacterial 
abundance
Gene 
richness
Lactobacilli Bifidobacteria Clostridia Enterococcus Roseburia Eubacteria Ruminococcus References
Fiber/prebi‑
otics
↑ ↑ ↑ ↑ ↓ ↑↓ [30, 64–66, 
69–76]
Resistant 
starch
↑ ↑ ↑ ↑ ↑ ↑ ↑ [3, 30, 
67–69, 
72–74]
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In addition to their effects on the makeup of the micro-
biota, and likely partially mediated by these effects, 
prebiotics also produce notable shifts in metabolic and 
immune markers. For instance, several groups observed 
reductions in the proinflammatory cytokine IL-6, insu-
lin resistance, and peak post-prandial glucose associ-
ated with intake of non-digestible carbohydrates present 
in whole grains [67, 78, 79]. One group additionally 
observed reductions in total body weight and concen-
trations of serum triglycerides, total cholesterol, LDL-
cholesterol, and hemoglobin A1c [79]. West et  al. [80] 
noted increased plasma levels of the anti-inflammatory 
cytokine IL-10 with consumption of butyrylated high 
amylose maize starch. The beneficial effect of prebiotics 
on immune and metabolic function in the gut is thought 
to involve increased production of SCFAs and strength-
ening of gastrointestinal-associated lymphoid tissue 
(GALT) from fiber fermentation [81].
Probiotics
Fermented foods containing lactic acid bacteria, such as 
cultured milk products and yogurt, represent a source of 
ingestible microorganisms that may beneficially regulate 
intestinal health and even treat or prevent inflamma-
tory bowel disease [82]. They are thought to accomplish 
this through their effects on the existing gut microbi-
ome (studies listed in Table  6), in addition to possible 
induction of anti-inflammatory cytokines such as IL-10 
[83]. Based on these properties, foods enriched for these 
modulatory microorganisms are referred to as probiot-
ics. Several groups have reported increased total bacte-
rial load after regular consumption of fermented milk 
or yogurt [84–87]. Notable increases in beneficial gut 
Bifidobacteria and/or Lactobacilli have also consistently 
been observed with several different types of probiot-
ics [85–97]. A randomized placebo-controlled trial of 60 
overweight healthy adults fed probiotics containing three 
strains of Bifidobacteria, four strains of Lactobacilli, and 
one strain of Streptococcus reported significant increases 
in the concentration of total aerobes, anaerobes, 
Lactobacillus, Bifidobacteria, and Streptococcus com-
pared to placebo. These subjects also had fewer total 
coliforms and Escherichia coli, as well as reduced triglyc-
erides, total cholesterol, LDL-cholesterol, VLDL-choles-
terol, and high-sensitivity C-reactive protein (hsCRP). 
HDL-cholesterol and insulin sensitivity improved after 
probiotic supplementation. Interestingly, the subjects 
with baseline low HDL, increased insulin resistance, and 
elevated hsCRP were noted to have significantly less total 
Lactobacilli and Bifidobacteria with more Escherichia 
coli and Bacteroides [98]. Probiotic-containing yogurt 
has also been shown to significantly reduce counts of the 
enteropathogens E. coli and Helicobacter pylori [94, 99].
Other reported health benefits from consuming fer-
mented dairy products include alleviation of GI intol-
erance symptoms [86, 100–102], accelerated intestinal 
transit time [96], increase in total serum IgA to potentiate 
the humoral immune response [90, 93, 94, 103], inhibi-
tion of pathogen adhesion to intestinal mucosa [104], and 
decreased abdominal distention and ascites in chronic 
liver disease patients [99]. One study that analyzed 
stool from diarrhea-predominant IBS patients identified 
reduced abundance of Lactobacillus [105]. Interestingly, 
Lactobacilli and Bifidobacteria have actually been used 
successfully for the prophylactic prevention of traveller’s 
diarrhea [106].
Polyphenols
Dietary polyphenols, which include catechins, flavonols, 
flavones, anthocyanins, proanthocyanidins and phe-
nolic acids, are actively studied for their antioxidant 
properties (studies listed in Table  7). Common foods 
with rich polyphenol content include fruits, seeds, veg-
etables, tea, cocoa products, and wine [107]. Commonly 
enriched bacterial genera amongst studies analyzing 
these food sources include Bifidobacterium and Lactoba-
cillus [56, 108–114]. Relative abundance of Bacteroides 
also was reported to increase in subjects consuming red 
wine polyphenols [110, 115, 116]. Bifidobacterium are 
a commonly used probiotic strain with recorded health 
Table 6 Effects of probiotics on gut microbiota
Bacterial 
abundance
Bifidobacteria Lactobacilli Streptococcus Total aerobes/
anaerobes
Total  
coliforms
Helicobacter 
pylori
Escherichia 
coli
References
Probiotics ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ [84–98]
Table 7 Effects of polyphenols on gut microbiota
Bifidobacteria Lactobacilli Bacteroides Clostridia Salmonella typhimurium Staphylococcus aureus References
Polyphenols ↑ ↑ ↓ ↓ ↓ ↓ [56, 108–116, 119–122]
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benefits such as immune-modulation, cancer prevention, 
and inflammatory bowel disease management [63]. In 
terms of further health benefits, consumption of cocoa-
derived polyphenols has been associated with significant 
increases in plasma HDL and significant reductions in 
plasma triacylglycerol and C-reactive protein concen-
trations [112, 117]. Additionally, a study examining the 
antibacterial activity of fruit polyphenols found high 
sensitivity to these compounds in the enteropathogens 
Staphylococcus aureus and Salmonella typhimurium 
[118]. Moreover, reductions in pathogenic Clostridium 
species (C. perfringens and C. histolyticum) have been 
noted after consumption of fruit, seed, wine, and tea 
polyphenols [108, 112, 113, 119–122].
Select diets
Several popular diets, including Western, gluten-free, 
omnivore, vegetarian, vegan, and Mediterranean, have 
been studied for their ability to modulate the intestinal 
microbiota (Fig.  4,  studies listed in Table  8). In several 
studies, a Western diet (high in animal protein and fat, 
low in fiber) led to a marked decrease in numbers of total 
bacteria and beneficial Bifidobacterium and Eubacterium 
species [26, 29, 48]. Consumption of a Western diet has 
also been associated with production of cancer-promot-
ing nitrosamines [123, 124].
Sanz et  al. had 10 healthy subjects consume a gluten-
free diet for 30  days. Populations of “healthy bacteria” 
decreased (Bifidobacterium and Lactobacillus), while 
populations of potentially unhealthy bacteria increased 
in parallel to reductions in polysaccharide intake after 
beginning the diet. In particular, increases were detected 
in numbers of E. coli and total Enterobacteriaceae, which 
may include further opportunistic pathogens [125]. 
Bonder et al. [126] similarly investigated the influence of 
a short-term gluten-free diet, noting reductions in Rumi-
nococcus bromii and Roseburia faecis with increased Vic-
tivallaceae and Clostridiaceae.
Vegan and vegetarian diets are enriched in fermentable 
plant-based foods. One study compared vegan and veg-
etarian diets to an unrestricted control diet, and found 
that both vegans and vegetarians had significantly lower 
counts of Bifidobacterium and Bacteroides species [127] 
(p  <  0.001). Interestingly, another study found a very 
modest difference in the gut microbomes of vegan versus 
omnivorous subjects [128]. The discrepancy between the 
two studies may be due to different methodologies for 
microbiome profiling (culture- vs sequencing-based), dif-
ferent control group diets, and/or host genetics. Future 
studies with careful experimental design will be needed 
to provide more insight into the differential effects of 
vegan and vegetarian diets on the gut microbiome.
Across the spectrum, the Mediterranean diet is highly 
regarded as a healthy balanced diet. It is distinguished by 
a beneficial fatty acid profile that is rich in both monoun-
saturated and polyunsaturated fatty acids, high levels of 
polyphenols and other antioxidants, high intake of fiber 
and other low glycemic carbohydrates, and relatively 
greater vegetable than animal protein intake. Specifically, 
olive oil, assorted fruits, vegetables, cereals, legumes, 
and nuts; moderate consumption of fish, poultry, and 
red wine; and a lower intake of dairy products, red meat, 
processed meat and sweets characterize the traditional 
Mediterranean diet [129]. De Filippis et  al. investigated 
Fig. 4 Impact of popular diets on intestinal microbiota and cardiometabolic disease. CVD cardiovascular disease, DM2 type 2 diabetes mellitus
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the potential benefits of the Mediterranean diet by com-
paring habitual omnivores, vegetarians, and vegans. They 
observed that the majority of vegans and vegetarians, but 
only 30% of omnivores, had high adherence to the Medi-
terranean diet. They detected significant associations 
between degree of adherence to the Mediterranean diet 
and increased levels of fecal SCFAs, Prevotella bacteria, 
and other Firmicutes. At the same time low adherence 
to the Mediterranean diet was associated with elevated 
urinary trimethylamine oxide, which is associated with 
increased cardiovascular risk [41]. Several other studies 
have shown that foods comprising the typical Mediter-
ranean diet also improve obesity, the lipid profile, and 
inflammation. These changes may be mediated by diet-
derived increases in Lactobacillus, Bifidobacterium, and 
Prevotella, and decreases in Clostridium [49, 110, 114, 
130–132].
Discussion
The ability to rapidly identify and quantify gut bacterial 
genera has helped us understand the impact of diet on 
host microbial composition. Studies that involve intake 
of a specific dietary component demonstrate how certain 
bacteria tend to respond to the nutrient-specific chal-
lenge. Protein, fats, digestible and non-digestible carbo-
hydrates, probiotics, and polyphenols all induce shifts in 
the microbiome with secondary effects on host immuno-
logic and metabolic markers. For instance, animal protein 
intake positively correlates with overall microbial diver-
sity, increases abundance of bile-tolerant organisms such 
as Bacteroides, Alistipes, and Bilophila, and reduces rep-
resentation of the Roseburia/E. rectale group. A high-sat-
urated fat diet seems to increase counts of total anaerobic 
microflora and the relative abundance of Bacteroides and 
Bilophila. Human studies have not reported that a high-
unsaturated fat diet significantly alters the gut bacterial 
profile; however, mouse studies have reported increases 
in Actinobacteria (Bifidobacterium and Adlercreut-
zia), lactic acid bacteria (Lactobacillus and Streptococ-
cus), and Verrucomicrobia (Akkermansia muciniphila). 
Both digestible and non-digestible carbohydrates are 
commonly reported in the literature to enrich Bifidobac-
terium and suppress Clostridia, while only non-digestible 
carbohydrates are noted to additionally enrich for Lacto-
bacillus, Ruminococcus, Eubacterium rectale, and Rose-
buria. Lastly, both probiotics and polyphenols enhance 
Bifidobacterium and lactic acid bacteria, while reducing 
enteropathogenic Clostridia species.
Maintaining a healthy gut microbiome is critical to human 
health
An increasing body of evidence suggests that our gut 
microbiome has a profound impact on our health. In the 
past decade, gut microorganisms have been shown to play 
a role in a wide range of human diseases, including obe-
sity, psoriasis, autism, and mood disorders [133–136]. The 
close relationship between diet, the gut microbiome, and 
health suggests that we may possibly improve our health 
by modulating our diet. One way in which microbiota can 
influence host health is by modulating host immunity. 
Studies in germ-free animals have demonstrated that the 
gut microbiome is essential for immune cell recruitment 
and differentiation [137]. Further investigations have 
revealed more specific roles for some bacterial species 
in mediating host immunity and immunologic diseases. 
In particular, the segmented filamentous bacteria have 
been found to promote autoimmune arthritis through an 
enhanced Th17 response [20, 138]. On the other hand, lac-
tic acid bacteria and Bifidobacteria are known to secrete 
factors that dampen inflammation by downregulating 
NF-κB dependent gene expression, IL-8 secretion, and 
levels of macrophage-attracting chemokines [139]. Lactic 
acid bacteria and Bifidobacteria have also been shown to 
directly downregulate T effector-mediated inflammatory 
responses while upregulating anti-inflammatory T regula-
tory cell expression in mice [140]. The exact mechanism 
of how these gut flora modulate immune responses is 
still not well understood; however, several studies sug-
gest that microbial-derived SCFAs may be contributing 
via G-protein-coupled receptor and epigenetic mecha-
nisms [141, 142]. Intestinal SCFAs have also been shown 
to directly increase the abundance of T regulatory cells in 
Table 8 Effects of special diets on gut microbiota
UFA unsaturated fatty acids
Diet Food constitu-
ents
Total 
bacteria
Bifidobacteria Lactobacilli Prevotella Eubacteria Rose‑
buria
Bacte‑
roides
Enterobacteria References
Western High animal fat/
protein
↓ ↓ ↓ ↓ ↑ ↑ [26, 29, 48]
Mediter‑
ranean
High fiber/antioxi‑
dants/UFA low 
red meat
↑ ↑ ↑ ↑ ↑ ↑ ↑ [41, 129, 192]
Gluten‑
free
No gluten ↓ ↓ ↓ ↓ ↓ ↓ ↑ [125, 126, 
193–195]
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the gut and to protect against allergic airway inflamma-
tion [17, 143–145]. In addition, they may inhibit the tran-
scription factor NF-κB, leading to decreased secretion of 
several pro-inflammatory cytokines [130]. Gut flora can 
also modulate host immunity through epigenetic modi-
fications. For example, microbial-derived butyrate inhib-
its histone deacetylases 6 and 9, which leads to increased 
acetylation in the promoter of the FOXP3 gene and higher 
regulatory T cell proliferation [142]. Reduced methyla-
tion in the promoters of proinflammatory genes TLR2 
and FFAR3 is correlated with reduced abundance of Fae-
calibacterium prausnitzii in type 2 diabetes patients [146, 
147]. Clearly our gut microbiome has diverse effects on 
host immunity, and a balanced gut flora is critical for a 
healthy immune system (Table 9).
Besides immunity, gut microorganisms have also been 
shown to impact host metabolic health. Individuals with 
metabolic disorders such as obesity and diabetes have 
been shown to have intestinal dysbiosis in relation to 
healthy individuals [148, 149]. Further characterization 
of the link between the gut microbiome and obesity has 
revealed several bacterial groups that may specifically 
contribute to the disease. In particular, obese individu-
als have a high baseline Firmicutes to Bacteroidetes ratio. 
In these subjects, reduction of caloric intake was noted 
to lower the Firmicutes to Bacteroidetes ratio [148]. 
Intriguingly, hosts with a gut microbiome dominated by 
Firmicutes have altered methylation in the promoters of 
genes that are linked to cardiovascular disease and obesity 
[150]. Additionally, Lactobacillus spp. have been shown 
to alleviate obesity-associated metabolic complications 
[151, 152]. The beneficial effects of Lactobacillus may be 
attributed to interactions with obesity-promoting bac-
teria in the gut and direct modulation of host immunity 
and gut barrier function [153]. Interestingly, the mucus-
degrading bacteria A. muciniphila has also been linked 
to a healthy metabolic profile. Obese individuals with 
a higher baseline relative abundance of A. muciniphila 
tend to have greater improvements in obesity-associated 
metabolic parameters (insulin tolerance, plasma triglycer-
ides and body fat distribution) after dietary intervention 
[154]. Interestingly, germ-free mice are more resistant to 
diet-induced obesity, possibly due to enhanced fatty acid 
metabolism in the absence of certain microflora [155]. 
Together, these findings demonstrate the important role 
of gut microbiota in maintaining host metabolic integrity 
(Table 10).
Conclusion and future directions
In conclusion, review of the literature suggests that diet 
can modify the intestinal microbiome, which in turn has 
a profound impact on overall health. This impact can 
Table 9 Effects of dietary components on immune parameters
SCFA short chain fatty acids, TLR toll-like receptor activation, WAT white adipose tissue inflammation, Met Endo metabolic endotoxemia, LPS lipopolysaccharide levels, 
CRP C-reactive protein, IL-6 interleukin-6, IL-10 interleukin-10, IgA immunoglobulin A
SCFA TLR WAT Met Endo LPS CRP IL-6 IL-10 IgA References
Prebiotics ↑ ↓ ↓ ↑ [67, 78–81, 120]
Probiotics ↑ ↓ ↑ ↑ [83, 88, 97–99, 103]
Polyphenols ↓ ↑ [115, 117, 122]
Unsaturated fat ↓ ↓ ↓ ↓ [50, 120]
Saturated fat ↑ ↑ ↑ ↑ [37, 52, 53, 58]
Animal protein ↓ [39–41]
Pea protein ↑ [31]
Table 10 Effects of dietary components on metabolic parameters
Chol cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglycerides, IGF-1 insulin-like growth factor-1
Total chol LDL-chol HDL-chol Plasma TG Insulin sensitivity IGF-1 production References
Prebiotics ↓ ↓ ↓ ↑ [73, 83, 84]
Probiotics ↓ ↓ ↑ ↓ ↑ [104]
Polyphenols ↑ ↓ [110, 117, 122]
Unsaturated fat ↓ ↓ [41]
Saturated fat ↓ [51–53]
Animal protein ↑ [42]
Artificial sweeteners ↓ [59]
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be beneficial or detrimental, depending on the relative 
identity and abundance of constituent bacterial popu-
lations. For example, it has been shown that a high-fat 
diet adversely reduces A. muciniphila and Lactobacil-
lus, which are both associated with healthy metabolic 
states [53]. This observation provides a good example of 
how dietary intervention might potentially be used to 
manage complex diseases, such as obesity and diabetes. 
Furthermore, advances in microbiome research have sug-
gested novel therapeutic possibilities for diseases that 
have traditionally been difficult to treat. For example, the 
fecal microbiota transplant has been used successfully to 
manage several different conditions, including ulcerative 
colitis, Clostridium difficile-associated colitis, irritable 
bowel syndrome, and even obesity [156–160]. It is possi-
ble that dermatologic conditions, including psoriasis and 
atopic dermatitis, may also be observed to benefit from 
re-engineering the gut microbiota. Recent advances in 
microbiome research offer exciting new tools to possibly 
enhance human health. Most of the studies reviewed in 
this manuscript profiled the microbiome using 16S rRNA 
amplicon sequencing, which utilizes the hypervariable 
regions of the bacterial 16S rRNA gene to identify bacte-
ria present in biological samples. 16S rRNA sequencing 
is the most commonly used method by medical research-
ers to study microbial composition, due to its low cost 
and relatively easy workflow for sample preparation and 
bioinformatic analyses. However, 16S rRNA amplicon 
sequencing primarily provides information about micro-
bial identity and not function. In order to investigate the 
microbiome’s functions, many researchers have turned 
to a shotgun metagenomic approach in which the whole 
bacterial genome is sequenced. Despite a higher cost and 
more complicated bioinformatics requirement, shotgun 
metagenomics provides information about both micro-
bial identity and gene composition. Knowing which genes 
are encoded by the bacteria present in a sample allows 
researchers to better understand their roles in human 
health. With reducing costs of next generation sequenc-
ing, improved sample preparation protocols, and more 
bioinformatic tools available for metagenomic analysis, 
this technique will be a powerful tool to study microbi-
ome functionality. Performing meta-analyses to correlate 
the microbiome with host genomes, transcriptomes, and 
immunophenotypes represents another exciting avenue 
for investigating human and bacterial interactions.
Precision medicine is another attractive, novel thera-
peutic approach for many diseases with strong genetic 
associations. It is important to note that the host geno-
type also plays a role in shaping the microbiome, and that 
this host-microbe interaction is crucial for maintaining 
human health [161]. Therefore, a better understanding of 
the interplay between genes, phenotypes, and the micro-
biome will provide important insights into the utility of 
precision medicine.
The observation that diet can modulate host-microbe 
interactions heralds a promising future therapeutic 
approach. Already, the gut microbiome has been found 
to influence the response to cancer immunotherapy [162, 
163]. Indeed, personalized nutrition is an emerging con-
cept that utilizes a machine-learning algorithm to pre-
dict metabolic responses to meals [164, 165]. This tool 
has broad implications for individualized patient care 
through dietary modification. While this and other tech-
nology is in the process of being refined and validated, 
further research using large, long-term clinical trials to 
evaluate a greater variety of food components would be 
helpful in making specific dietary recommendations to 
patients.
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